With the introduction of imaging agents based on prostate-specific membrane antigen (PSMA) inhibitors, PSMA-mediated surgery is starting to claim a prominent role in prostate cancer (PCa) treatment [1, 2]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.